Switch antidepressants: When? How? Why?;Changer d'antidépresseur: Quand, comment, pourquoi?

Encephale

Volumn 37, Issue SUPPL. 1, 2011, Pages

  Gourion, D ^a   Galinowski, A ^a   Baraille, L ^b   Picard, H ^b  

^a Laboratoires Lilly France ^*  (France)

^b Lilly France   (France)

Author keywords

Antidepressant; Drug refractory depression; Response; Switch

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LITERATURE; PATIENT COMPLIANCE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG SUBSTITUTION; DRUG TOXICITY; HUMANS; MEDICATION ADHERENCE; TREATMENT FAILURE;

EID: 79956190250     PISSN: 00137006     EISSN: 00137006     Source Type: Journal    
DOI: 10.1016/j.encep.2010.06.008     Document Type: Article

References (51)

1. AFSSAPS. Bon usage des médicaments antidépresseurs dans le traitement des troubles dépressifs et des troubles anxieux de l'adulte. Argumentaire. Octobre 2006. http://www.afssaps.sante.fr.
2. ANAES. Prise en charge d'un épisode dépressif isolé de l'adulte en ambulatoire. Service des recommandations et réfé rences professionnelles. Avril 2002.
3. APA. 2004. Treating major depressive disorder. A quick reference guide. http://www.psych.org/psych-pract/treatg/quick-ref-guide/MDD-QRG.pdf.
4. D. Bakish Psychopharmacology for the clinician. How does one switch from one antidepressant to another when there has been a treatment failure? Rev Psychiatr Neurosci 23 4 1998 264
5. D. Bakish New standard of depression treatment: remission and full recovery J Clin Psychiatry 62 Suppl. 26 2001 5 9 (Pubitemid 34003368)
6. J.P. Boulenger Traitements antidépresseurs : critres d'évaluation du résultat thérapeutique Encéphale 33 2007 S666 S671
7. J. Brunner, T. Bronisch, and M. Uhr Proteomic analysis of the CSF in unmedicated patients with major depressive disorder reveals alterations in suicide attempters Eur Arch Psychiatry Clin Neurosci 255 2005 438 440 (Pubitemid 43029833)
8. S. Caccia Metabolism of the newer antidepressants, an overview of the pharmacological and pharmacokinetic implications Clin Pharmacokinet. 34 4 1998 281 302 (Pubitemid 28163404)
9. H.C. Driscoll, J.F. Karp, and M.A. Dew Getting better, getting well: understanding and managing partial and non-response to pharmacological treatment of non-psychotic major depression in old age Drugs Aging 24 10 2007 801 814 (Pubitemid 47553790)
10. M. Fava Management of non-response and intolerance: switching strategies J Clin Psychiatry 61 Suppl. 2 2000 10 12 (Pubitemid 30131897)
11. M. Fava, D.L. Dunner, and J.H. Greist Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial J Clin Psychiatry 62 6 2001 413 420 (Pubitemid 32717873)
12. M. Fava, G.I. Papakostas, and T. Petersen Switching to bupropion in fluoxetine-resistant major depressive disorder Ann Clin Psychiatry 15 1 2003 17 22 (Pubitemid 36723637)
13. S.J. Fredman, M. Fava, and A.S. Kienke Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices J Clin Psychiatry 61 6 2000 403 408 (Pubitemid 30452205)
14. B.N. Gaynes, A.J. Rush, and M.H. Trivedi The STAR*D study: treating depression in the real world Clev Clinic J Med. 75 1 2008 57 66
15. Haute Autorité de Santé (HAS). Synthse des recommandations professionnelles. Prise en charge des complications évolutives d'un épisode dépressif caractérisé de l'adulte. Avril 2007. http://www.has-sante.fr.
16. R.M. Hirschfeld The use of mirtazapine in difficult-to-treat patient populations Hum Psychopharmacol. 17 Suppl. 1 2002 S33 S36
17. R.M.A. Hirschfeld, S.A. Montgomery, and E. Aguglia Partial response and non response to antidepressant therapy: current approaches and treatment options J Clin Psychiatry 63 2002 826 837
18. F. Holsboer How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 9 8 2008 638 646
19. R.H. Howland Sequenced treatment alternatives to relieve depression (STAR*D). Part 1: study design J Psychosocial Nursing. 46 9 2008 21 24
20. R.H. Howland Sequenced treatment alternatives to relieve depression (STAR*D). Part 2: study outcomes J Psychosocial Nursing 46 10 2008 21 24
21. M. Ising, S. Lucae, and E. Binder A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression Arch Gen Psychiatry 66 9 2009 966 975
22. L.B. Marangell Switching antidepressants for treatment-resistant major depression J Clin Psychiatry 62 Suppl. 18 2001 12 17 (Pubitemid 33736200)
23. S.C. Marcus, M. Hassan, and M. Olfson Antidepressant switching among adherent patients treated for depression Psychiatr Serv. 60 5 2009 617 623
24. A.A. Nierenberg, N.E. McLean, and J.E. Alpert Early nonresponse to fluoxetine as a predictor of poor 8-week outcome Am J Psychiatry. 152 10 1995 1500 1503
25. A.A. Nierenberg, A.H. Farabaugh, and J.E. Alpert Timing of onset of antidepressant response with fluoxetine treatment Am J Psychiatry. 157 9 2000 1423 1428
26. D. Nutt, K. Demyttenaere, and Z. Janka The other face of depression, reduced positive affect: the role of catecholamines in causation and cure J Psychopharmacol. 21 5 2007 461 471 (Pubitemid 47106935)
27. G.I. Papakostas, T. Petersen, and K.G. Sklarsky Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder Psychiatry Res. 149 1-3 2007 195 200 (Pubitemid 46108106)
28. G.I. Papakostas, M. Fava, and M.E. Thase Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches Biol Psychiatry 63 7 2008 699 704 (Pubitemid 351329277)
29. E.S. Paykel, R. Ramana, and Z. Cooper Residual symptoms after partial remission: an important outcome in depression Psychol Med. 25 1995 1171 1180
30. A. Pelissolo Douleurs corporelles dans la dépression : prévalence et importance clinique Presse Med 38 3 2009 385 391
31. D.G. Perahia, D. Quail, and D. Desaiah Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques J Clin Psychiatry 69 1 2008 95 105 (Pubitemid 351282002)
32. M.F. Poirier, and P. Boyer Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison Br J Psychiatry 175 1999 12 16 [Erratum in: Br J Psychiatry 1999;175:394] (Pubitemid 29307849)
33. F.M. Quitkin, P.J. McGrath, and J.W. Stewart Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry 53 9 1996 785 792 (Pubitemid 26303619)
34. H.G. Ruhé, J. Huyser, and J.A. Swinkels Switching antidepressant after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review J Clin Psychiatry 67 2006 1836 1855 (Pubitemid 46055194)
35. A.J. Rush, M. Fava, and S.R. Wisniewski Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design Control Clin Trials 25 1 2004 119 142 (Pubitemid 38230109)
36. A.J. Rush, H.C. Kraemer, and H.A. Sackeim Report by the ACNP Task Force on response and remission in major depressive disorders Neuropsychopharmacology 31 2006 1841 1853
37. A.J. Rush, M.H. Trivedi, and S.R. Wisniewski Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression N Engl J Med 354 12 2006 1231 1242 [23]
38. A.J. Rush, M.H. Trivedi, and S.R. Wisniewski Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report Am J Psychiatry 163 2006 1905 1917 (Pubitemid 44807782)
39. A.J. Rush, S.R. Wisniewski, and D. Warden Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features Arch Gen Psychiatry 65 8 2008 870 880
40. C. Spadone, M. Sylvestre, and P. Chiarelli Management strategies for major depressive episodes as a function of initial response to an SSRI or SNRI antidepressant: results of the ORACLE survey Encéphale. 31 6 Pt 1 2005 698 704
41. A. Szegedi, M.J. Müller, and I. Anghelescu Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression J Clin Psychiatry 64 4 2003 413 420 (Pubitemid 36547285)
42. M.E. Thase, A.R. Entsuah, and R.L. Rudolph Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors Br J Psychiatry 178 2001 234 241 (Pubitemid 32183606)
43. M.E. Thase, A.J. Rush, and R.H. Howland Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression Arch Gen Psychiatry 59 3 2002 233 239 (Pubitemid 34212500)
44. M. Tochigi, K. Iwamoto, and M. Bundo Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains Neurosci Res 60 2008 184 191
45. M.H. Trivedi, and S.M. Baker Clinical significance of monitoring early symptom change to predict outcome J Clin Psychiatry. 62 Suppl. 4 2001 27 33 [discussion 37-40] (Pubitemid 32183562)
46. M.H. Trivedi, A.J. Rush, and S.R. Wisniewski Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice Am J Psychiatry 163 1 2006 28 40 (Pubitemid 43050100)
47. M.H. Trivedi Major depressive disorder: remission of associated symptoms J Clin Psychiatry 67 Suppl. 6 2006 27 32 (Pubitemid 44078110)
48. M.H. Trivedi, E. Hollander, and D. Nutt Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression J Clin Psychiatry 69 2 2008 246 258 (Pubitemid 351469268)
49. VidalPro 2009. http://www.vidalpro.net.
50. M.M. Wohlreich, C.H. Mallinckrodt, and J.G. Watkin Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine Annals Clin Psychiatry 17 4 2005 259 268 (Pubitemid 41780249)
51. M.M. Wohlreich, J.M. Martinez, and C.H. Mallinckrodt An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches J Clin Psychopharmacol. 25 6 2005